Access to Fertility Treatment and Care Act
SB 2408, the Access to Fertility Treatment and Care Act, would create a broad federal requirement that health coverage include fertility treatment whenever a plan covers obstetrical services. The bill defines fertility treatment expansively to include fertility preservation, artificial insemination, in vitro fertilization and other assisted reproductive technologies, embryo genetic testing, fertility medications, gamete donation, and other related services the Secretary of Health and Human Services deems appropriate. It also requires coverage even when a person has not been formally diagnosed with infertility, so long as the treatment is medically appropriate and provided by or at a compliant facility.
The bill applies this coverage mandate across multiple systems: private group and individual health plans under the Public Health Service Act, ERISA-covered employer plans, and plans in the Internal Revenue Code; the Federal Employees Health Benefits Program; TRICARE; veterans’ fertility services; state Medicaid plans; and Medicare. It also includes notice requirements, anti-discrimination and anti-retaliation provisions, and limits on cost-sharing so fertility treatment cannot be subject to higher deductibles or coinsurance than comparable medical services. The bill sets different effective dates depending on the program, with some provisions beginning 180 days after enactment, Medicaid in October 2026, and Medicare services in January 2026.
The overall sentiment reflected in the available record is neutral to supportive in design, but the bill has not yet advanced beyond introduction and referral to the Senate Health, Education, Labor, and Pensions Committee. There are no recorded votes or committee transcript excerpts in the provided material, so no formal legislative debate is available. The structure and breadth of the bill suggest an intent to standardize fertility coverage across major public and private health coverage arrangements.
The main points of potential contention are likely to be cost, scope, and federal preemption. Because the bill requires coverage for a wide range of fertility services, including IVF and embryo genetic testing, insurers, employers, and public programs could face higher spending obligations. Another likely issue is the bill’s mandate that coverage be provided even without a formal infertility diagnosis, which expands eligibility beyond many existing fertility-benefit rules. The bill also reaches into state Medicaid programs and federal benefit systems, which may raise concerns about administrative burden, implementation timelines, and the extent to which federal law would override existing state insurance standards.
The bill would amend the Public Health Service Act, ERISA, the Internal Revenue Code, the Federal Employees Health Benefits statute, Title 10 for TRICARE, Title 38 for veterans’ health care, the Social Security Act for Medicaid and Medicare, and related conforming provisions. In practical terms, it would require many health plans and public coverage programs to add fertility treatment as a covered benefit whenever obstetrical services are covered, while limiting cost-sharing and prohibiting discriminatory exclusions or provider gag rules. It would also create new federal standards that would supersede inconsistent plan terms and likely preempt contrary state insurance rules for ERISA-covered plans.
Based on the text and the absence of recorded opposition or vote history, the bill appears to be framed as a pro-access health coverage measure with a generally supportive policy posture. The sponsor’s approach is comprehensive and rights-oriented, emphasizing equal access, nondiscrimination, and parity with obstetrical coverage. However, because the bill is only at the referral stage and no hearing transcript or vote data is provided, there is no documented legislative consensus or formal opposition in the available record.
Likely areas of contention include the cost of mandating fertility coverage across private insurance, federal employee plans, military coverage, Medicaid, and Medicare; whether the mandate should apply only to people diagnosed with infertility; and whether the bill goes too far by covering advanced reproductive technologies such as IVF, embryo genetic testing, and gamete donation. Insurers, employers, and budget-conscious policymakers may object to the breadth of required benefits and the limits on cost-sharing, while supporters are likely to argue that fertility care should be treated like other medically necessary reproductive health services and not restricted by diagnosis-based barriers.